Pfizer-sponsored symposium at ISICEM 2023

Tuesday 21st March 2023 | 12:30–13:30 (CET) | Gold Hall

From admission to discharge: reflections on early, appropriate treatment of MDR Gram-negative bacterial infections in the ICU

By reflecting on the challenging scenarios that are faced within the ICU and that can influence treatment strategies and outcomes, this meeting aims to:

- Review the patient journey for MDR Gram-negative bacterial infections through practical patient case studies, and explore the critical factors that drive effective treatment decision-making
- Recognise how pivotal clinical studies, real-world evidence, recommendations, and guidelines can be practically applied to support therapeutic selection
- Provide clinical scenarios in which ceftazidime–avibactam could be considered early and appropriately to improve patient outcomes
- Discuss the importance of the multidisciplinary team in ensuring appropriate and optimal decision-making

Agenda

Chair: Professor Mervyn Singer (UK)

12:30 » Welcome and introduction
   Professor Mervyn Singer

12:35 » From admission to discharge: reflections of an ICU specialist
   Dr Tim Rahmel (Germany)

12:50 » From admission to discharge: reflections of an ID specialist
   Dr Carolina Garcia-Vidal (Spain)

13:05 » Panel discussion and Q&A – working closely with the multidisciplinary team to improve patient outcomes
   All faculty

13:25 » Summary and close
   Professor Mervyn Singer

ICU, intensive care unit; ID, infectious disease; MDR, multidrug-resistant.

The SmPC for Zavicefta (ceftazidime–avibactam) can be found here.

©2023 Pfizer Inc. All rights reserved.

This symposium is initiated, organised and funded by Pfizer Inc. ©2023 Pfizer Inc. All rights reserved.